[go: up one dir, main page]

MX2024014315A - Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas - Google Patents

Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas

Info

Publication number
MX2024014315A
MX2024014315A MX2024014315A MX2024014315A MX2024014315A MX 2024014315 A MX2024014315 A MX 2024014315A MX 2024014315 A MX2024014315 A MX 2024014315A MX 2024014315 A MX2024014315 A MX 2024014315A MX 2024014315 A MX2024014315 A MX 2024014315A
Authority
MX
Mexico
Prior art keywords
treatment
amido
compounds useful
liver diseases
heteroaromatic compounds
Prior art date
Application number
MX2024014315A
Other languages
English (en)
Inventor
Daniel Tor Pettersen
Erik Lars Malmerberg
Tord Bertil Inghardt
Jan Åke Lindberg
Jens Peter Brandt
Björn Erik Anton Holm
Stéphanie Marcelle Gueret
Nidhal Selmi
Jon Paul Janet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024014315A publication Critical patent/MX2024014315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La memoria descriptiva se refiere a compuestos de Fórmula (I): (ver Fórmula) y a sales farmacéuticamente aceptables de los mismos, a procesos y a productos intermedios usados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de enfermedades tales como enfermedad hepática.
MX2024014315A 2022-05-19 2024-11-19 Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas MX2024014315A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263364976P 2022-05-19 2022-05-19
US202263367843P 2022-07-07 2022-07-07
US202263383982P 2022-11-16 2022-11-16
PCT/EP2023/063424 WO2023222850A1 (en) 2022-05-19 2023-05-18 Amido heteroaromatic compounds useful in the treatment of liver diseases

Publications (1)

Publication Number Publication Date
MX2024014315A true MX2024014315A (es) 2024-12-06

Family

ID=86646721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014315A MX2024014315A (es) 2022-05-19 2024-11-19 Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas

Country Status (25)

Country Link
US (2) US20230373983A1 (es)
EP (2) EP4514782B1 (es)
JP (1) JP7770594B2 (es)
KR (1) KR20250016177A (es)
CN (1) CN119173506A (es)
AU (1) AU2023274003B2 (es)
CA (1) CA3256765A1 (es)
CL (1) CL2024003495A1 (es)
CO (1) CO2024017138A2 (es)
CR (1) CR20240536A (es)
DK (1) DK4514782T3 (es)
DO (1) DOP2024000239A (es)
FI (1) FI4514782T3 (es)
HR (1) HRP20251564T1 (es)
IL (1) IL316898A (es)
LT (1) LT4514782T (es)
MA (1) MA70477B1 (es)
MX (1) MX2024014315A (es)
PE (1) PE20250791A1 (es)
PT (1) PT4514782T (es)
RS (1) RS67515B1 (es)
SM (1) SMT202500465T1 (es)
TW (1) TW202411224A (es)
UY (1) UY40282A (es)
WO (1) WO2023222850A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104697A1 (en) 2023-11-16 2025-05-22 Astrazeneca Ab Heteroaromatic 17beta hydroxy steroid dehydrogenase 13 inhibitors
TW202521529A (zh) * 2023-11-16 2025-06-01 瑞典商阿斯特捷利康公司 脲嘧啶化合物
WO2025104564A1 (en) * 2023-11-16 2025-05-22 Astrazeneca Ab Crystalline form of an amido heteroaromatic compound

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
JPH0696532B2 (ja) 1988-08-11 1994-11-30 山之内製薬株式会社 血小板活性化因子拮抗剤
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
AR041508A1 (es) 2002-08-09 2005-05-18 Astra Ab Compuestos con actividad en los receptores de glutamato metabotropicos
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
AU2008257158A1 (en) 2007-05-22 2008-12-04 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
JP2012505898A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
EP2550266B1 (en) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
KR101559883B1 (ko) 2013-10-30 2015-10-13 동국대학교 산학협력단 2-아미노치환 옥사디아졸 유도체, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
US20170290337A1 (en) 2014-09-24 2017-10-12 Syngenta Participations Ag Herbicidal Pyridino-/Pyrimidino-Thiazoles
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
US11795162B2 (en) * 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
MA52365A (fr) 2018-04-25 2021-03-03 Yumanity Therapeutics Inc Composés et leurs utilisations
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
WO2020156241A1 (zh) 2019-01-31 2020-08-06 中国医药研究开发中心有限公司 芳环或芳杂环类化合物及其制备方法和医药用途
EP3994125B1 (en) 2019-07-02 2025-12-24 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
WO2021050555A1 (en) 2019-09-10 2021-03-18 X-Chem, Inc. Compositions and uses thereof
WO2021138450A1 (en) 2019-12-30 2021-07-08 Buto Corporation Novel small molecule shc blockers for treating liver disease and metabolic disease
WO2021211974A1 (en) 2020-04-18 2021-10-21 Inipharm, Inc. Hsd17b13 inhibitors and uses thereof
IL298475A (en) * 2020-06-09 2023-01-01 Anima Biotech Inc Collagen-1 translation inhibitors and methods of their use
US20230278978A1 (en) * 2020-07-24 2023-09-07 Inipharm, Inc. Thiophene hsd17b13 inhibitors and uses thereof
AU2021310936A1 (en) * 2020-07-24 2023-03-09 Inipharm, Inc. Quinazolinone HSD17B13 inhibitors and uses thereof
CA3190258A1 (en) 2020-08-18 2022-02-24 Metrea Biosciences, Inc. Compounds and methods of modulating 17.beta.-hydroxysteroid dehydrogenase type 13
MX2023003678A (es) * 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
JP2023544157A (ja) * 2020-09-30 2023-10-20 エフエル２０２２－００１， インコーポレイテッド Ｈｓｄ１７ｂ１３阻害剤及びその使用
CN116744918A (zh) * 2020-09-30 2023-09-12 Fl2022-001公司 Hsd17b13抑制剂和其用途
IL302764A (en) 2020-11-13 2023-07-01 Inipharm Inc Dichlorophenol HSD17B13 inhibitors and their uses
US20240132431A1 (en) 2021-01-06 2024-04-25 Chugai Seiyaku Kabushiki Kaisha Method for alkylating acidic functional group
US20250154686A1 (en) 2021-01-06 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Compound library
EP4319872A4 (en) 2021-04-05 2025-03-12 Inipharm, Inc. Thiazole/isothiazole hsd17b13 inhibitors and uses thereof
US20240208929A1 (en) 2021-04-05 2024-06-27 Inipharm, Inc. Hydroxypyridine hsd17b13 inhibitors and uses thereof
US20220380378A1 (en) 2021-04-22 2022-12-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
BR112023025112A2 (pt) 2021-06-01 2024-02-20 Syngenta Crop Protection Ag Derivados microbiocidas de tetrahidroisoquinolina
US20250100993A1 (en) 2022-01-26 2025-03-27 Inipharm, Inc. 2-substituted thiazole hsd17b13 inhibitors and uses thereof

Also Published As

Publication number Publication date
MA70477B1 (fr) 2025-12-31
EP4635494A2 (en) 2025-10-22
US12291524B2 (en) 2025-05-06
KR20250016177A (ko) 2025-02-03
PT4514782T (pt) 2025-12-15
JP2025516080A (ja) 2025-05-26
WO2023222850A1 (en) 2023-11-23
US20250011311A1 (en) 2025-01-09
CL2024003495A1 (es) 2025-04-04
SMT202500465T1 (it) 2026-01-12
AU2023274003B2 (en) 2026-01-29
EP4514782B1 (en) 2025-09-10
AU2023274003A1 (en) 2025-01-02
CR20240536A (es) 2025-01-29
DK4514782T3 (da) 2025-12-15
DOP2024000239A (es) 2024-12-30
HRP20251564T1 (hr) 2026-01-30
LT4514782T (lt) 2025-12-29
EP4635494A3 (en) 2025-12-31
UY40282A (es) 2023-11-15
PE20250791A1 (es) 2025-03-14
IL316898A (en) 2025-01-01
CA3256765A1 (en) 2023-11-23
JP7770594B2 (ja) 2025-11-14
RS67515B1 (sr) 2025-12-31
EP4514782A1 (en) 2025-03-05
FI4514782T3 (fi) 2025-12-10
TW202411224A (zh) 2024-03-16
CN119173506A (zh) 2024-12-20
US20230373983A1 (en) 2023-11-23
CO2024017138A2 (es) 2025-03-06

Similar Documents

Publication Publication Date Title
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
ZA202107444B (en) Nlrp3 inflammasome inhibitors
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
MX2024004327A (es) Moleculas pequeñas para el tratamiento del cancer.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
HRP20050967A2 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
ZA202400595B (en) Spirocyclic compounds
MX2025002086A (es) Inhibidores novedosos de inflamasoma nlrp3
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
PH12021551232A1 (en) Haloallylamine compounds and application thereof
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
SE0401655D0 (sv) New compounds
MX2023015246A (es) Compuestos pirimidinicos para usar como inhibidores de map4k1.
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
EP4248960A3 (en) Novel triterpene derivatives as hiv inhibitors
NZ700507A (en) Pyrimidine derivatives for the treatment of bacterial diseases
ATE317380T1 (de) Bernsteinsäurederivate